Dechert Advises Diffusion Pharmaceuticals in Merger with EIP Pharma Inc.

Dechert advised Diffusion Pharmaceuticals Inc. in connection with a proposed merger with EIP Pharma Inc. Expected to close in mid-2023, the definitive merger agreement for an all-stock transaction will form a publicly traded, combined company that will focus on the advancement of EIP Pharma’s pioneering pipeline of oral stress kinase inhibitors. The combined company is expected to be renamed “CervoMed” and continue to trade on the Nasdaq Capital Market under a new ticker symbol, CRVO.

Diffusion Pharmaceuticals Inc. is a biopharmaceutical company focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most. EIP Pharma, Inc. is a privately held clinical-stage biotechnology company advancing CNS-focused therapeutics to benefit patients with a range of debilitating neurodegenerative diseases.

The Dechert team advising Diffusion Pharmaceuticals includes corporate partner David Rosenthal, counsel John Alessi, and associates Laura Xie and Nicholas Pullen; additional corporate counsel Seth Ray, special counsel Francois Quintard-Morenas, and associates Nicholas Chionchio and Devyn Kurpis; tax partner Kevin Zaragoza and associate Abigail Hopper; intellectual property associates Frank Hwang and Danielle Paglia; employment benefits partner Kevin Kay, and associates Tabitha Crosier and Brie Michaelson; litigation partner Neil Steiner and associate James Smith.

About Dechert 

Dechert is a leading global law firm with 21 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.